WIN 4th SYMPOSIUM recognized by Leading Oncology Society
Paris, June 4, 2012 - The scientific program of the 4th WIN Symposium, on Cancer personalized medicine and efficacy of biomarkers, a major event where hundred of representatives from 30 countries will gather on next June 28 and 29, 2012 in Paris (France), has been endorsed by the American Society of Clinical Oncology (ASCO)®, the world’s leading professional organization representing physicians who care for people with cancer.
John Mendelsohn, Chairman of WIN Consortium and Director of the Institute for personalized therapy, UT M. D. Anderson Cancer Center, says: “we have been proud to receive the endorsement of ASCO® for the quality of educational content of the WIN Symposium Program 2012. This is a great achievement and recognition of the scientific value of the WIN Program Symposium and the major impact this symposium may bring“.
“The WIN Consortium meeting reflects the vision and goals of ASCO’s blueprint for transforming cancer research (www.ASCO.org/Blueprint) and the potential that molecularly-driven therapies have to transform clinical research,” said Sandra Swain, MD, President of ASCO. “ASCO is pleased to endorse this meeting because of the opportunities it provides for international collaboration.”
Organized by the WIN Consortium, this congress gathers the main opinion leaders in cancer care and drug development for two days of debates and exchanges and offers an excellent opportunity to advance research in Cancer and biomarkers at international level, facilitating the translation of scientific results into clinical practice. Advanced and innovative concepts to increase efficacy of personalized cancer therapeutics and molecular diagnostics will be disclosed during WIN Symposium: launch of WINTHER, the most advanced study in personalized medicine selected by the European Community EU FP7; launch of the Universal Bio Marker technology for early diagnostic.